Companies › AVEO Pharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Other, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ficlatuzumab (AV-299) Hepatocyte growth factor inhibitor | HGF | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | Aug 2027 |
| AV-380 anti-GDF-15 monoclonal antibody | GDF15 | Phase 1 | Cachexia | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05865535 | AV-380 | Phase 1 | Cachexia | Other | Dec 2026 |
| NCT06064877 | Ficlatuzumab (AV-299) | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | Oncology | Aug 2027 |
CatalYm Kexing Biopharm Pfizer Claris Biotherapeutics Kringle Pharma
Celltrion CatalYm Samsung Bioepis Orca Biosystems Grit Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.